News and Trends 23 Jun 2022 Scancell to produce and clinically validate T cell redirecting bispecific antibodies Scancell Holdings plc, which develops immunotherapies for the treatment of cancer and infectious disease, has announced it will develop its GlyMab antibodies into T cell redirecting bispecific (TCB) antibodies and take them into the clinic. The UK company said this is a promising new therapeutic approach to treat cancer. TCB antibodies have dual-binding specificity, which […] June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Krystal Biotech looks for FDA approval for dystrophic epidermolysis bullosa treatment U.S. gene therapy company Krystal Biotech, Inc, has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of B-VEC (beremagene geperpavec) for the treatment of patients with dystrophic epidermolysis bullosa (DEB). B-VEC is an investigational non-invasive, topical gene therapy designed to treat DEB at the molecular level by […] June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 23 Jun 2022 The biggest Asia-Pacific biotech investments in May 2022 Healthcare-focused biotech companies won the biggest private investments in the Asia-Pacific region in May 2022, led by a $100 million Series A from the Chinese anti-inflammatory drug developer Reistone Biopharma. In the Asia-Pacific region, Chinese biotechs generally took home the biggest private funding rounds in May 2022. The top rank went to Reistone Biopharma, located […] June 23, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Gemelli Biotech to work on gastrointestinal diseases with new $19M funding U.S.-headquartered Gemelli Biotech Corp, which focuses on precision diagnostics for gastrointestinal (GI) diseases, has completed a $19 million series A finance round. Blue Ox Healthcare Partners, a private equity firm providing growth capital to companies targeting precision health and value-based care, led the investment round, joined by founding investor Cedars-Sinai, along with Carolina Angel Network, […] June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 BRIM Biotechnology enters OTC trading in Taiwan BRIM Biotechnology, Inc.has entered OTC (over the counter) trading in Taiwan. Established in July 2013, BRIM is a clinical-stage company developing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases. The company’s current paid-in capital is approximately $23 million. BRIM has several novel drug products in its pipeline, all underpinned by […] June 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2022 Shanghai biotech secures $80 million to advance products A bio-manufacturing company based in Shanghai has bagged $80 million in funding to advance its bio-based supplies. Mojia Biotech said it would use the funds to commercialize its Viridimin brand of animal-feed additives, scale up manufacturing capacity for Aliphane series of bio-based materials, advance its product pipeline and expand its global research and development capabilities. […] June 23, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Sponsored by Merck 23 Jun 2022 How a global network accelerated the development of a virus-like particle vaccine against Covid-19 Vaccines are among the most effective ways to improve and protect human health. Whereas vaccines in Europe and North America are regarded as part of the general medical plan, vaccine supply has always been a pressing issue in African countries. In the current Covid-19 pandemic, the ability to develop and manufacture vaccines in Africa instead […] June 23, 2022 - 5 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Roquefort Therapeutics buys UK biotech in return for shares Medical biotechnology company, Roquefort Therapeutics, has conditionally agreed to buy UK biotech Oncogeni Ltd in return for shares. Oncogeni develops novel patented cancer medicines, and will receive 50 million shares, worth just under £4 million ($4.9 million). Acquisition In light of the acquisition, Oncogeni co-founder Ajan Reginald will become chief executive of the group, and […] June 22, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Millions invested for progression of Lyme disease vaccine Pfizer has agreed to invest €90.5 million ($95 million) towards a vaccination for Lyme disease. A deal has been struck with Valneva SE that will see the start of the phase 3 study of the disease’s vaccine candidate, VLA15. This is scheduled for the third quarter of this year. The investment will represent 8.1% of […] June 22, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 US Toddlers and children to receive Covid-19 vaccine after emergency approval granted Emergency authorization was granted for the use of the Pfizer-BioNTech Covid-19 vaccines on children from six months old to under five years of age. The US Food and Drug Administration made the authorization on Friday (June 17). All children ages 6 months and up are now eligible to receive the COVID-19 vaccine, following the US […] June 22, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Rensselaer researchers make face masks to fight viruses Researchers at Rensselaer Polytechnic Institute in Troy, NY, have developed N95 surgical face masks that are not just barriers to bacteria and viruses, but can also destroy them. The team said the antiviral, antibacterial masks can be worn for longer, creating less waste as the masks do not need to be replaced as frequently. Helen […] June 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Cystic fibrosis in the crosshairs as Carbon Biosciences launches with $38M funding Carbon Biosciences, a Longwood Fund founded biotech company developing parvovirus-derived gene therapies, has launched with $38 million of financing led by Agent Capital. Agent is joined by Longwood Fund, Astellas Venture Management LLC, the Cystic Fibrosis Foundation, Solasta Ventures, University of Tokyo Innovation Platform (UTokyoIPC), and Camford Capital. Massachusetts-based Carbon is harnessing novel parvovirus vectors […] June 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email